Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 5 → 6·10:11, 4 Aug 2024
Difference between revision 5 and revision 6 of Adverse effects of GLP-1 receptor agonists. 2 lines changed; the page grew by 275 bytes.
| Revision 5 — 23:16, 25 Jul 2024 StubSorterBot (talk) bot: expand PMID to full citation 2,045 bytes ±0 | Revision 6 — 10:11, 4 Aug 2024 EndotoxinEd (talk) fix a broken wikilink 2,320 bytes +275 | ||
|---|---|---|---|
| 20 | Frequencies are from placebo-controlled trials and the placebo arms are not zero — nausea is reported by 10–20% of placebo participants in the same trials, so the attributable excess is smaller than the raw figure.{{r|wilding2021}} | 20 | Frequencies are from placebo-controlled trials and the placebo arms are not zero — nausea is reported by 10–20% of placebo participants in the same trials, so the attributable excess is smaller than the raw figure.{{r|wilding2021}} |
| 21 | 21 | ||
| + | 22 | Attenuation over time parallels the attenuation of the gastric-emptying delay, and is the reason escalation schedules work: adaptation to the gastrointestinal effect occurs while the appetite and glycaemic effects persist. See [[Dose escalation schedule]].{{r|drucker2018}} | |
| + | 23 | ||
| 22 | == References == | 24 | == References == |
| 23 | {{reflist}} | 25 | {{reflist}} |